The pivotal role of IL-6 and Cx43-signalling identified here highlights these pathways as potential therapeutic targets to reduce the risk of arrhythmia following hiPSC-CMs transplant post-MI. This evidence concerns the gene GJA1 and cardiac arrhythmia.